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Introduction {#sec001}
============

Shiga toxin-producing *Escherichia coli* (STEC) is an enteric pathogen that causes diarroheal illness in humans which can lead to hemorrhagic colitis and haemolytic uremic syndrome (HUS), one of the main causes of renal failure in children \[[@pone.0139803.ref001]\]. Shiga toxins produced by this pathogen play an important role in causing these clinical manifestations. Currently, there is no treatment available for human STEC infections other than supportive care as the administration of antibiotics can exacerbate the disease. STEC O157:H7 is the predominant serotype associated with human infections in North America, while non-O157:H7 serotypes such as O103, O26, O111 are more prevalent in many European countries, South America and parts of Australia \[[@pone.0139803.ref001],[@pone.0139803.ref002],[@pone.0139803.ref003]\] The main reservoir for STEC is ruminants \[[@pone.0139803.ref004]\] and therefore intervention strategies aimed at lowering the levels of this pathogen in cattle could ultimately result in improved human health \[[@pone.0139803.ref005]\].

During the process of infection, STEC uses a Type Three Secretion System (T3SS) to inject virulence factors known as effector proteins directly into host cells, leading to the formation of attaching and effacing lesions (A/E) lesions, which are hallmarks of STEC infections. The major structural components of the STEC T3SS include EspA (filament), EspB and EspD (translocon complex) \[[@pone.0139803.ref006]\]. The STEC T3SS secretes over 50 effector proteins that are encoded on the LEE Pathogenicity Island or elsewhere on the chromosome (non-LEE effectors) \[[@pone.0139803.ref007]\]. The translocated intimin receptor, Tir, is an effector protein which enters host cells and forms a receptor that binds to intimin that is expressed on the surface of STEC cells \[[@pone.0139803.ref006]\]. Many studies have shown that the STEC T3SS is essential for colonization of cattle, implying that this is a major virulence factor employed by this pathogen \[[@pone.0139803.ref008],[@pone.0139803.ref009],[@pone.0139803.ref010]\].

Vaccination of cattle with STEC~O157~ T3SP's has shown to be an effective strategy in reducing the shedding of STEC~O157~ \[[@pone.0139803.ref011],[@pone.0139803.ref012],[@pone.0139803.ref013],[@pone.0139803.ref014],[@pone.0139803.ref015],[@pone.0139803.ref016],[@pone.0139803.ref017],[@pone.0139803.ref018],[@pone.0139803.ref019]\]. However, this protection appears to be serotype specific \[[@pone.0139803.ref020],[@pone.0139803.ref021]\]. Therefore, alternative antigens need to be identified that offer protection against non-O157 STEC serotypes. Recently, it has been shown that anti-sera to an extract of STEC~O157~ T3SPs had the highest degree of cross-reactivity with STEC~O103~ recombinant T3SPs \[[@pone.0139803.ref020]\], suggesting that STEC~O103~ T3SPs may have cross-protective potential. In this study, we tested the effect of sera against STEC~O103~ recombinant proteins on STEC~O103~ and STEC~O157~ adherence to HEp-2 cells. Moreover, we tested the vaccine potential of the recombinant proteins against STEC~O103~ challenge in mice.

Materials and Methods {#sec002}
=====================

Bacterial strains and growth conditions {#sec003}
---------------------------------------

The bacterial strains used in this study comprised of *E*. *coli* N01-2454 (O103:H2), EDL933 (O157:H7), CL9 (O26:H11) and CL101 (O111:NM) \[[@pone.0139803.ref022],[@pone.0139803.ref023]\]. For cloning and protein expression, we used the *E*. *coli* K-12 lab strains, JM109 (*end*A1, *rec*A1, *gyr*A96, *thi*, *hsd*R17 (r~k~ ^--^, m~k~ ^+^), *rel*A1, *sup*E44, Δ (*lac-pro*AB), \[F´ *tra*D36, *pro*AB, *laq*I^q^ZΔM15\]) and BL21 (F^-^, *dcm*, *ompT*, *hsdS* ~*B*~ (r~B~ ^-^,m~B~ ^-^), *gal*, λ(DE3)) obtained from Qiagen and Invitrogen, respectively. The strains were grown in Luria Bertani (LB) medium at 37°C in an orbital shaker (250 rpm), unless otherwise stated. *E*. *coli* serotypes O103 and O157 were transformed with a green fluorescent protein expressing plasmid, pNR78, for visualization by flouresence microscopy during the adherence inhibition assays as described \[[@pone.0139803.ref021]\]. Plasmid pNR78 was constructed in our lab by amplifying the GFP gene from pQBI-25 (Quantum Biotechnologies) which was cloned downstream of the GroEL promoter.

Protein expression and purification {#sec004}
-----------------------------------

The STEC serotype O103:H2 T3SS genes *escC*, *espA*, *espB*, *espF*, *espG*, *espR1*, *nleA*, *nleE*, *nleF*, *nleG2*, *nleH*, *sepD*, *tccp2* and *tir* were amplified by PCR (Applied Biosystems) based on the sequence provided by GenBank^®^. Similarly, for cross reactivity studies, *espA*, *espB*, *espF*, *nleA* and *tir* from STEC serotypes O26 and O111 were amplified by PCR. The genes were cloned in either pQE-30 (Qiagen), pET-15b (Novagen), pGEX-5X-1 (GE Healthcare) or pGEX-5X-3, of which the first two are 6x His-tagged protein expression vectors while the latter are Glutathione *S*-transferase (GST)-fusion expression vectors. The constructs were confirmed by PCR and sequencing (Plant Biotechnology Institute, Saskatoon). Proteins were expressed in *Escherichia coli* K-12 lab strains (JM109 or BL21) and purified using either the method described in the QIAexpressionist™ manual (Qiagen) for His-tagged proteins or the GST Gene Fusion System Handbook (GE Healthcare) for the GST-fusion protein. Purified protein samples were greater than 90% pure as determined by SDS-PAGE followed by Coomassie blue staining as described previously \[[@pone.0139803.ref020]\].

Raising polyclonal anti-sera to STEC~O103~ T3SS recombinant proteins {#sec005}
--------------------------------------------------------------------

Purified recombinant proteins (100 μg each) were formulated with 30% Emulsigen D (MVP Laboratories) and two New Zealand White rabbits (Charles River) per STEC~O103~ recombinant protein were immunized subcutaneously on day 0, followed by booster injections on days 21 and 42. The rabbits were euthanized on day 56 and sera were collected. Antibody titers against STEC~O103~ recombinant proteins were confirmed using ELISA in duplicate wells as previously described \[[@pone.0139803.ref020]\]. For antibody titer determinations, the cut-off value was considered to be the average of the blank and two standard deviations. All rabbits used in this study were handled and treated in accordance with the guidelines provided by the Canadian Council on Animal Care (CCAC) as administered by the University Committee on Animal Care and Supply (UCACS), protocol 1994--213. This protocol was approved by the UCACS at the University of Saskatchewan for the present study.

Cell culture {#sec006}
------------

HEp-2 cells (ATCC^®^ CCL-23^™^, CEDARLANE^®^) were grown in HyClone Dulbecco modified Eagle medium (DMEM; Thermo Scientific) supplemented with 10% fetal bovine serum (FBS; PAA Laboratories) and 1% HEPES Buffer (Invitrogen) at 37°C in a 5% CO~2~ incubator. One day prior to the adherence inhibition assays, 10^5^ cells per well were seeded onto eight well chamber slides (Nunc) and allowed to incubate overnight.

Adherence inhibition assays {#sec007}
---------------------------

Adherence of STEC~O103~ and STEC~O157~ to HEp-2 cells was assessed using an assay described elsewhere \[[@pone.0139803.ref021]\]. Briefly, an overnight culture of STEC grown in LB media was subcultured (1:100) into DMEM containing 10% FBS and 1% HEPES Buffer for 2 hours (until the OD~600~ was 0.2) at 37°C and 5% CO~2~ without shaking. For testing the effect of pooled sera against STEC~O103~ T3SPs on adherence, HEp-2 cells were infected with 25 μl of STEC (1.7 x 10^6^ colony forming units), 10 μl of each serum and 225 μl fresh DMEM. The effect of individual anti-serum was tested by infecting HEp-2 cells with 25 μl of STEC (1.7 x 10^6^ CFU), 20 μl of anti-serum and 225 μl fresh DMEM (anti-O103 antibodies were prepared as described previously \[[@pone.0139803.ref021]\]). The chamber slides were incubated at 37°C and 5% CO~2~ for 3 hours (STEC~O157~) or 3.5 hours (STEC~O103~). The slides were washed six times with 200 μl Phosphate Buffered Saline (PBS, 0.1M pH 7.2) and fixed with 200 μl PBS containing 3.7% Formaldehyde. This was followed by two washes with PBS after which the slides were allowed to air dry. Coverslips were mounted with Vectashield^®^ (Vector) containing DAPI and sealed. The slides were visualized under the fluorescent microscope (Axiovert 200 inverted microscope--Zeiss). Bacteria were observed under FITC, while HEp-2 cells were observed under DAPI. Each experimental group was first tested using 2 replicate wells in an 8 well chamber slide and 4 random grids were examined per well under the fluorescent microscope as described below. After observing clear differences in STEC adherence to HEp-2 cells between the different treatments, the experiments were repeated independently on a separate occasion using 8 replicates per test group as previously published \[[@pone.0139803.ref021]\] with 4 random grids per well used for enumerating the number of STEC per HEp-2 cell. The resulting pictures (4 under FITC and 4 under DAPI) per well (total of 8 pictures per well) were used to enumerate the number of STEC and HEp-2 cells per well. The total numbers of STEC per grid were then divided by the total numbers of HEp-2 cells per grid to determine the number of STEC per HEp-2 cell in one grid. This was repeated for the 8 duplicate wells per group, resulting in a total of 64 pictures per test group. Each data point in Figs [1](#pone.0139803.g001){ref-type="fig"} and [2](#pone.0139803.g002){ref-type="fig"} represent the average number of STEC per HEp-2 cell from 4 counts (4 random grids) per well. For statistical analysis, the median STEC per HEp-2 cell across the different test groups were compared using a non-parametric analysis as described below.

![Inhibition of STEC~O103~ adherence to HEp-2 cells by either (A) pooled sera against recombinant STEC~O103~ T3SPs or (B and C) individual serum samples specific for STEC~O103~ recombinant proteins EspB, EspF, EspG or NleA.\
Anti-O103 refers to antibodies against a secreted fraction of T3SPs from STEC~O103~. Values are expressed as median bacteria per cell from 8 replicates. \*, *P* \< 0.05; \*\*, *P* \< 0.01; \*\*\*, *P* \< 0.001; \*\*\*\*, *P* \< 0.0001.](pone.0139803.g001){#pone.0139803.g001}

![Inhibition of STEC~O157~ adherence to HEp-2 cells by pooled sera against recombinant STEC~O103~ T3SPs.\
(A) STEC~O157~ adherence to HEp-2 cells was significantly lower in the presence of antibodies against STEC~O103~ EspA, EspB, EspF, NleA and Tir. (B) STEC~O157~ adherence was partially lower in the presence of STEC~O103~ anti-EspA and anti-Tir or anti-EspB, anti-EspF and anti-NleA. Values are expressed as median bacteria per cell from 8 replicates. \*\*, *P* \< 0.01; \*\*\*\*, *P* \< 0.0001.](pone.0139803.g002){#pone.0139803.g002}

Immunization of mice with STEC~O103~ T3SPs {#sec008}
------------------------------------------

Twenty four BALB/C mice were obtained from Charles River Canada. Mice were housed at the VIDO Animal Care Facility (University of Saskatchewan) and handled in accordance with the guidelines provided by the CCAC as administered by the UCACS, protocol 1998--0003. This protocol was approved by the UCACS at the University of Saskatchewan for the present study. Mice were randomly divided into two groups with 12 mice per group. The mice were immunized subcutaneously on Day 0 with 100 μl of either PBS (0.1M, pH 7.2) or a pool of STEC~O103~ recombinant proteins EspA, EspB, EspF, NleA and Tir (1 μg of each protein) followed by a second immunization at Day 21. The vaccines were formulated with 30% Emulsigen D (MVP Laboratories). Sera were collected prior to both immunizations on day 0 and day 21 as well as prior to challenge with STEC~O103~ on day 35. Antibody titers were determined using ELISA in duplicate wells as described previously \[[@pone.0139803.ref020]\]. For antibody titer determinations, the cut-off value was considered to be the average of the blank and two standard deviations. The mice were challenged as described below.

STEC mouse colonization model {#sec009}
-----------------------------

For colonization of mice, we used the streptomycin-treated model as previously described \[[@pone.0139803.ref024],[@pone.0139803.ref025]\]. Briefly, mice were given water containing Streptomycin Sulfate (5 g/L) on day 32 for two days. Subsequently, mice were deprived of food and water for 24 hours. On Day 35, mice were orally challenged with 100 μl of 10^9^ cfu of STEC~O103~ Nal^r^ (resuspended in 20% sucrose). The mice were permitted access to food and water containing Streptomycin for the rest of the experiment. Fecal pellets were collected every 3 days for 21 days post challenge. Shedding of STEC~O103~ was monitored by incubating the fecal samples in 1 ml LB broth for 2 hours at room temperature to allow the pellets to soften. The samples were vortexed, serially diluted in PBS and plated on MacConkey Sorbitol Agar containing Nalidixic Acid (15 μg/ml), Cefixime (5 μg/ml) and Potassium Tellurite (2.5 μg/ml). The plates were incubated overnight at 37°C and STEC colonies were enumerated the following day. Bacterial counts were expressed as cfu per gram of fecal content.

Cross-reactivity of STEC~O103~ T3SS recombinant protein specific sera {#sec010}
---------------------------------------------------------------------

Purified STEC~026~ and STEC~0111~ EspA, EspB, EspF, NleA and Tir recombinant proteins were separated by SDS-PAGE and transferred to a nitrocellulose membrane using a Mini Trans-Blot Electrophoretic Cell (Bio-Rad) as per the manufacturer's instructions. The membranes were probed with either polyclonal sera (1:2500) from mice vaccinated with a pool of the corresponding STEC~O103~ recombinant proteins or with rabbit polyclonal sera (1:2500) raised against STEC~O103~ EspA, EspB, EspF, NleA and Tir. Alkaline phosphatase labeled goat anti-mouse or goat anti-rabbit IgG (KPL) antibodies were used as secondary antibodies (1:2000). The membranes were developed using 5-bromo-4-chloro-3-indolyl phosphate (BCIP) and nitroblue tetrazolium (NBT) salt according to the manufacturer's instructions (Sigma).

Statistical analyses {#sec011}
--------------------

Statistical Analyses were performed using GraphPad Prism 6.02. Adherence inhibition assays were analyzed using a non-parametric analysis (Kruskal-Wallis test) and individual groups were tested using Dunn's multiple comparison test. Mouse antibody titers were presented as medians plus/minus the 25^th^ and 75^th^ percentile ranges. Differences in immune responses between the vaccine and control groups were tested using non-parametric repeated measures ANOVA. A *P* value of \< 0.05 was considered significant.

Results {#sec012}
=======

Immune responses against STEC~O103~ recombinant proteins in rabbits {#sec013}
-------------------------------------------------------------------

Polyclonal sera were raised against 14 STEC~O103~ recombinant proteins in rabbits in order to test the adherence inhibition effect of the sera in vitro and for cross reactivity studies. All the recombinant proteins induced a significant IgG specific antibody response as determined by ELISA ([Table 1](#pone.0139803.t001){ref-type="table"}). The mean IgG titer across all the proteins was 911,801, while NleE had the lowest antibody titer (151,399) and EspR1 had the highest antibody titer (2,771,000).

10.1371/journal.pone.0139803.t001

###### IgG antibody titers specific for STEC~O103~ recombinant proteins in rabbits.

![](pone.0139803.t001){#pone.0139803.t001g}

                   Pre-immune   Day 56
  ---------------- ------------ ---------
  **Anti-EscC**    87.5         241547
  **Anti-EspA**    882.5        838090
  **Anti-EspB**    783.5        1256000
  **Anti-EspF**    711          618333
  **Anti-EspG**    773.5        846100
  **Anti-EspR1**   789.5        2771000
  **Anti-NleA**    2778         1332000
  **Anti-NleE**    555.5        151399
  **Anti-NleF**    2748.5       1036000
  **Anti-NleG2**   652          1358000
  **Anti-NleH**    499.5        614552
  **Anti-SepD**    536.5        483176
  **Anti-Tccp2**   252.5        402873
  **Anti-Tir**     122.5        816244

Antibody titers were determined by setting the cut-off value as the average of the blank and two standard deviations. All serum samples were tested in duplicate wells.

Antibodies against STEC~O103~ T3SP's inhibit adherence of STEC~O103~ {#sec014}
--------------------------------------------------------------------

To test the effect of rabbit polyclonal sera against recombinant STEC~O103~ T3SPs on adherence, we used a functional assay where we measured the level of STEC~O103~ adherence to HEp-2 cells. Our results demonstrate that pooled sera against STEC~O103~ recombinant proteins significantly reduced adherence of STEC~O103~ to HEp-2 cells relative to the group incubated with pre-immune sera ([Fig 1A](#pone.0139803.g001){ref-type="fig"}). In order to determine which serum samples were involved in this adherence inhibition effect, we tested specific anti-sera to EspA, EspB, EspF, EspG, EscC, EspR1, NleA, NleE, NleF, NleG2, NleH, SepD, Tir and Tccp2 individually in duplicate. We observed that sera against EspB, EspG, EspF and NleA were involved in blocking adherence (data not shown). To confirm this observation, we performed an adherence inhibition assay where sera against EspB, EspG, EspF and NleA were tested individually with 8 replicates. The data clearly suggest that anti-sera to these four proteins were also highly effective in blocking STEC~O103~ adherence to HEp-2 cells compared to the group treated with pre-immune serum ([Fig 1B and 1C](#pone.0139803.g001){ref-type="fig"}).

Anti- STEC~O103~ T3SP sera have cross-protective potential {#sec015}
----------------------------------------------------------

In order to determine if antibodies against STEC~O103~ recombinant proteins can block adherence of other STEC serotypes, we evaluated the effect of pooled sera on STEC~O157~ adherence to HEp-2 cells. Interestingly, our results indicate that incubation of STEC~O157~ with anti-sera to STEC~O103~ EspA, EspB, EspF, NleA and Tir significantly lowered adherence to HEp-2 cells, while anti-sera to the other proteins did not have a major effect ([Fig 2A](#pone.0139803.g002){ref-type="fig"}). We further investigated this adherence inhibition effect by testing pooled sera against STEC~O103~ EspA and Tir in one group and sera against EspB, EspF and NleA in another group. Adherence of STEC~O157~ to HEp-2 cells was lower in both groups relative to the control group ([Fig 2B](#pone.0139803.g002){ref-type="fig"}) but not to the same level as in the pooled group ([Fig 2A](#pone.0139803.g002){ref-type="fig"}). These results suggest that antibodies to STEC~O103~ EspA, EspB, EspF, NleA and Tir proteins have a combined effect on blocking STEC~O157~ adherence and that they have cross-protective potential.

Immunization of mice with T3SP's from STEC~O103~ induces a strong humoral response but does not affect fecal shedding {#sec016}
---------------------------------------------------------------------------------------------------------------------

In order to test the protective capacity of STEC~O103~ effectors, mice were vaccinated subcutaneously with a pool of recombinant proteins and were subsequently infected with STEC~O103~ by oral challenge. Two weeks following the booster immunization, significant EspA-, EspB-, NleA- and Tir--specific IgG titers were detected in the sera relative to the control group ([Table 2](#pone.0139803.t002){ref-type="table"}). In contrast, immunization with EspF elicited a weak IgG specific serum response. To assess the protective capacity of our vaccine, fecal shedding of STEC~O103~ was monitored over 21 days post challenge. The levels of STEC~O103~ were similar in both vaccinates and non-vaccinates throughout the duration of the study, suggesting that antibodies against the antigens used for immunization did not prevent STEC~O103~ from persisting in the intestine ([Fig 3](#pone.0139803.g003){ref-type="fig"}), or that the response was not of sufficient magnitude.

![STEC~O103~ shedding in feces following oral challenge in mice.\
Mice were immunized subcutaneously with either PBS (control) or a pool of STEC~O103~ EspA, EspB, EspF, NleA and Tir followed by a booster immunization three weeks later. Two weeks after the second immunization, mice were orally challenged with 10^9^ cfu of STEC~O103~. N = 12 for both groups. Values are expressed as median cfu per gram of feces.](pone.0139803.g003){#pone.0139803.g003}

10.1371/journal.pone.0139803.t002

###### Median IgG antibody titers specific for STEC~O103~ EspA, EspB, EspF, NleA or Tir in mice vaccinated with either PBS or a pool of STEC~O103~ recombinant proteins.

![](pone.0139803.t002){#pone.0139803.t002g}

  Antibody        PBS   Vaccine       P                                                                      
  --------------- ----- ------------- ------ ------------- ------ ------------- --------- ------------------ ----------
  **Anti-EspA**   693   (590--853)    1089   (736--1462)   772    (581--860)    6979      (3109--11618)      0.0007
  **Anti-EspB**   235   (157--304)    600    (353--814)    243    (221--477)    294644    (195617--427747)   \<0.0001
  **Anti-EspF**   882   (742--1240)   1232   (973--5538)   1239   (753--1930)   3822      (1067--13092)      0.052
  **Anti-NleA**   481   (161--839)    2734   (422--7809)   552    (250--4314)   1019000   (5364--1385000)    0.0004
  **Anti-Tir**    570   (470--1154)   845    (711--3461)   517    (387--652)    280528    (151906--821988)   \<0.0001

Values are expressed as median titers. Numbers in parentheses represent the 25^th^-- 75^th^ percentile. Antibody titers were determined by setting the cut-off value as the average of the blank and two standard deviations. All serum samples were tested in duplicate wells.

STEC~O26~ and STEC~O111~ T3SS proteins display significant cross-reactivity with anti-sera to the corresponding STEC~O103~ proteins {#sec017}
-----------------------------------------------------------------------------------------------------------------------------------

The cross-reactivity of sera against STEC~O103~ T3SS proteins with other STEC serotypes including STEC~O26~ and STEC~O111~, was first tested by western blotting using rabbit polyclonal sera. Our results indicate that EspB~O111~, EspF~O111~ and NleA~O111~ reacted strongly with anti-sera to the corresponding STEC~O103~ proteins, while Tir~O111~ displayed a weaker reaction and EspA~O111~ did not react ([Fig 4A](#pone.0139803.g004){ref-type="fig"}). The western blot profile for STEC~O26~ proteins was similar with respect to EspB~O26~ and EspF~O26~. However, EspA~O26~ also reacted strongly, unlike EspA~O111~, while NleA~O26~ did not react ([Fig 4B](#pone.0139803.g004){ref-type="fig"}). Subsequently, sera from mice immunized with a pool of STEC~O103~ recombinant proteins was used to study the cross-reactivity with the equivalent STEC~O26~ and STEC~O111~ proteins. The results indicate that EspB~O26~ reacted strongly with the anti-sera while EspA~O26~, EspF~O26~ and NleA~O26~ did not ([Fig 5A](#pone.0139803.g005){ref-type="fig"}). In contrast, the western blot profile for the STEC~O111~ recombinant proteins showed a significant degree of cross reactivity for EspB~O111~, NleA~O111~ and Tir~O111~ ([Fig 5B](#pone.0139803.g005){ref-type="fig"}). Taken together, the results suggest that EspB~O103~, NleA~O103~, and Tir~O103~ possess significant cross-reactive properties with the corresponding proteins from STEC~O26~ and STEC~O111~. Hence, these proteins may form the basis of a cross-protective vaccine that confers protection against multiple STEC serotypes.

![Cross-reactivity of STEC~O103~ EspA, EspB, EspF, NleA and Tir specific rabbit polyclonal sera with the corresponding STEC~O26~ and STEC~O111~ recombinant proteins.\
(A) Western blot using anti-EspA. Lane 1, marker; Lane 2, EspA~O103~ (20.5 kDa); Lane 3, EspA~O26~ (20.5 kDa); Lane 4, EspA~O111~(20.5 kDa). (B) Western blot using anti-EspB. Lane 1, marker; Lane 2, EspB~O103~ (33.1 kDa); Lane 3, EspB~O26~ (33.2 kDa); Lane 4, EspB~O111~ (32.8 kDa). (C) Western blot using anti-EspF. Lane 1, marker; Lane 2, EspF~O103~ (57 kDa); Lane 3, EspF~O26~ (40 kDa); Lane 4, EspF~O111~ (27 kDa). (D) Western blot using anti-NleA. Lane 1, marker; Lane 2, NleA ~O103~ (44 kDa); Lane 3, NleA ~O26~ (11.7 kDa); Lane 4, NleA ~O111~ (47.5 kDa). (E) Western blot using anti- Tir. Lane 1, marker; Lane 2, Tir ~O103~ (56 kDa); Lane 3, Tir ~O111~ (56.9 kDa).](pone.0139803.g004){#pone.0139803.g004}

![Cross-reactivity of STEC~O103~ EspA, EspB, EspF, NleA and Tir specific mouse polyclonal sera with the corresponding STEC~O26~ and STEC~O111~ recombinant proteins.\
Western blot using sera from mice immunized with a combination of STEC~O103~ EspA, EspB, EspF, NleA and Tir to test the cross-reactivity with: (A) STEC~O26~ proteins. Lane 1, marker; Lane 2, EspA~O26~ (20.5 kDa); Lane 3, EspB~O26~ (33.2 kDa); Lane 4, EspF~O26~ (40 kDa); and Lane 5, NleA~O26~ (11.7 kDa). (B) STEC~O111~ proteins. Lane 1, marker; Lane 2, EspA~O111~ (20.5 kDa); Lane 3, EspB~O111~ (32.8 kDa); Lane 4, EspF ~O111~ (27 kDa); Lane 5, NleA ~O111~ (47.5 kDa); and Lane 6, Tir~O111~ (56.9 kDa).](pone.0139803.g005){#pone.0139803.g005}

Discussion {#sec018}
==========

Many efforts have been made to develop STEC~O157~ vaccines using the T3SS proteins as targets in order to reduce the levels of the pathogen in cattle \[[@pone.0139803.ref005],[@pone.0139803.ref012]\]. However, these vaccination strategies provide limited protection as they are directed only against STEC~O157~ and they are limited in their benefit \[[@pone.0139803.ref020],[@pone.0139803.ref021]\]. Non-O157 STEC serotypes are more prevalent in other parts of the world \[[@pone.0139803.ref001]\] and with the rise in non-O157 STEC infections in humans \[[@pone.0139803.ref026]\] as well as the increase in the prevalence of these serotypes in cattle \[[@pone.0139803.ref027]\], a vaccine that can confer protection against multiple serotypes is more desirable. The aim of this study was to determine if STEC~O103~ T3SS proteins could provide protection against STEC~O103~ as well as other heterologous serotypes using adherence-inhibition assays and the streptomycin-treated mouse model.

We used STEC~O103~ T3SS proteins as targets for a potentially cross protective vaccine since the T3SS proteins encoded by this serotype have previously been shown to have the highest degree of cross reactivity with STEC~O157~, relative to STEC~O26~ and STEC~O111~ \[[@pone.0139803.ref020],[@pone.0139803.ref021]\]. Based on this, we over-expressed and purified STEC~O103~ EscC, EspA, EspB, EspF, EspG, EspR1, NleA, NleE, NleF, NleG2, NleH, SepD, Tccp2 and Tir recombinant proteins. In order to test the protective capacity of these proteins, we first examined the effect of rabbit polyclonal sera against the candidate proteins in vitro using a HEp-2 cell adherence inhibition assay which has been successfully used as a functional assay to study STEC adherence \[[@pone.0139803.ref021],[@pone.0139803.ref028]\]. This, in turn, may reflect the effect of antibodies on intestinal colonization. Our results demonstrate that pooled sera against STEC~O103~ recombinant proteins significantly inhibited STEC~O103~ adherence. This is in agreement with the findings of Asper *et al*, where anti-sera to all STEC~O103~ secreted proteins blocked adherence by this serotype \[[@pone.0139803.ref021]\]. We also show for the first time that sera against individual STEC~O103~ recombinant proteins including, EspB, EspF, EspG and NleA, inhibited adherence of the bacteria to HEp-2 cells. Interestingly, pooled anti-sera to STEC~O103~ recombinant proteins EspA, EspB, EspF, NleA and Tir were able to block adherence of STEC~O157~, suggesting that these candidate proteins may provide protection against multiple STEC serotypes. However, it appears that the inhibition of STEC~O157,~ unlike that of STEC~O103~, was due to a combination of STEC~O103~ anti-sera since there was reduced inhibition of STEC~O157~ once the pooled anti-sera were divided into two groups. Taken together, this is the first report which illustrates that sera against STEC~O103~ T3SS recombinant proteins can block adherence of STEC~O157~ to HEp-2 cells.

The streptomycin-treated mouse model \[[@pone.0139803.ref024],[@pone.0139803.ref029]\] was used to test the efficacy of the identified candidate STEC~O103~ recombinant proteins as antigens for protection against STEC~O103~. This model was chosen since it has been widely used by various groups to test their STEC vaccines prior to conducting studies in cattle \[[@pone.0139803.ref025],[@pone.0139803.ref030],[@pone.0139803.ref031],[@pone.0139803.ref032],[@pone.0139803.ref033]\]. The mice developed strong serum IgG specific titers against EspA~O103~, EspB~O103~, NleA~O103~ and Tir~O103~ following immunization, while the response to the corresponding EspF recombinant protein was weak. The weak response to EspF~O103~ is in line with what was observed for EspF~O157~ in a previous study published by our group \[[@pone.0139803.ref020]\]. Immunization with STEC~O103~ recombinant proteins did not affect STEC~O103~ fecal shedding over the duration of the experiment relative to the control group. This was unexpected since similar STEC~O157~ based vaccines have been highly effective in mice \[[@pone.0139803.ref030],[@pone.0139803.ref033]\]. In addition, a recent vaccination study by our group illustrated that a combination of nine STEC~O157~ recombinant proteins was highly effective in controlling STEC~O157~ fecal shedding in mice (data not shown). It is possible that our STEC~O103~ vaccine may have been more effective against intestinal colonization had it been administered intranasaly. However, both subcutaneous and intranasal immunization of mice with an extract of STEC~O157~ secreted proteins as well as individual recombinant proteins have proven to be highly effective in controlling STEC~O157~ shedding \[[@pone.0139803.ref030]\]. In addition, the lack of a robust immune response against EspA may have contributed to the persistence of STEC~O103~ in the intestines. Alternatively, since very little work has been done on STEC~O103~ in mice, we speculate that the T3SS may play a different role in STEC~O103~ infection in mice. Therefore, further analysis of the STEC~O103~ T3SS may be required in mice, while a similar vaccine study should be performed in cattle with STEC~O103~.

The serological cross reactivity of STEC~O103~ recombinant proteins EspA, EspB, EspF, NleA and Tir with the corresponding STEC~O26~ and STEC~O111~ proteins was analyzed by western bloting. Overall our results indicate that there was significant cross reactivity of the STEC~O26~ recombinant proteins, EspA~O26~, EspB~O26~ and EspF~O26~ when rabbit polyclonal sera were used. These observations are supported by the protein sequence homology of the STEC~O26~ proteins to STEC~O103~: EspA~O26~ (92%), EspB~O26~ (99%) and EspF~O26~ (91%). The fact that NleA~O26~ did not cross react was not unexpected since the STEC~O26~ genome contains an NleA-like gene which encodes for an 11 kDa protein, while the actual size of NleA~O103~ is 44 kDa. Therefore, sequence homology between NleA~O103~ and NleA~O26~ is expected to be low (58%) with few shared epitopes, if any. We did not show the results for Tir~O26~ since we were unable to express or purify this protein despite numerous attempts. This may be explained by the fact that Tir~O26~ may require co-expression and co-purification with a chaperone \[[@pone.0139803.ref034]\]. The western blot profile for STEC~O111~ recombinant proteins EspB~O111~, EspF~O111~, NleA~O111~ showed a high degree of cross reactivity with the corresponding sera, while there was lower cross reactivity with Tir~O111~. This is consistent with the observed sequence homologies between the STEC~O103~ and STEC~O111~ proteins: EspB~O111~ (71%), EspF~O111~ (70%), NleA (83%) and Tir (65%). The fact that EspA~O111~ did not react to sera against EspA~O103~ was surprising since EspA~O111~ shares greater than 81% sequence homology to EspA~O103~. The serological cross reactivity of the STEC serotypes O26 and O111 recombinant proteins was remarkably lower when mouse polyclonal sera were used. The difference in the results may be due to differences in recognition of epitopes by the mouse and rabbit immune systems. Overall, the data from both cross reactivity studies suggests that EspB~O103~, NleA~O103~ and Tir~O103~ are highly cross reactive and have the potential to form an efficacious recombinant vaccine that protects cattle not only against STEC~O103~ but other STEC serotypes as well. This finding is supported by two recent studies which demonstrate that EspB~O157~ and Tir~O157~ are immunogenic and protective in cattle against STEC~O157~ \[[@pone.0139803.ref035],[@pone.0139803.ref036]\]. Although these studies provide important information about STEC~O157~, this can be used as a basis for conducting similar studies with STEC~O103~ to test for cross serotype protection.

Vaccination with a commercially available STEC~O157~ T3SS vaccine (Econiche^™^) is an effective strategy to control STEC shedding in cattle \[[@pone.0139803.ref037]\]. Many recent studies have proven that this preslaughter intervention does lead to reduced levels of this pathogen in cattle \[[@pone.0139803.ref038],[@pone.0139803.ref039]\]. Moreover, Mathews *et al* have recently predicted that vaccination of cattle against STEC~O157~ will have a significant impact on public health by lowering human STEC infections by 85% \[[@pone.0139803.ref040]\]. Our in vitro results are the first steps towards a vaccine that may provide protection against multiple STEC serotypes, which is highly desirable for both North America as well as other regions where non-O157 STEC serotypes are more prevalent. The STEC~O157~ SRP^®^ vaccine (contains siderophore and porin proteins) has also shown to be effective in reducing fecal shedding in cattle \[[@pone.0139803.ref041],[@pone.0139803.ref042]\]. However, this vaccine also confers limited serotype protection like the Econiche^™^ vaccine \[[@pone.0139803.ref043],[@pone.0139803.ref044]\]. Taken together, the need for an STEC vaccine that provides protection against more than one serotype is required and our in vitro results suggest that STEC~O103~ may be a likely candidate, though further testing is required in cattle.
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